AbbVie backs an Italian startup focused on autoimmune diseases; BioTheryX advances AML drug with $35M D round
Italy’s Enthera Pharmaceuticals has grabbed a €28 million launch round to back its work on, laying bragging rights to the largest A round ever for an Italian biotech.
The company is using “nontraditional” tech to target autoimmune diseases, looking to re-establish stem cell capabilities in type 1 diabetes and inflammatory bowel disease.
Graziano Seghezzi, managing partner of Sofinnova Partners, co-seeded the company, with AbbVie stepping in to help out. This is AbbVie’s first investment in the Italian biotech scene.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.